Compare iShares Silver Trust (SLV) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Silver Trust vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? iShares Silver Trust trades at $54.56 (market cap $29.58B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.16B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is the larger of the two by market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.36% dividend while iShares Silver Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Silver Trust for 89 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| SLV | TAK | |
|---|---|---|
Market Cap | $29.58B | $58.16B |
Volume | 20,364,955 | 2,467,530 |
52-Week High | $105.57 | $19.05 |
52-Week Low | $42.40 | $13.23 |
Typical Hold Time | 89 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $86.04B |
Dividend Yield | — | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLV (iShares Silver Trust) is trading at $53.82, down 2.94% amid broader precious metals pressure from rising Treasury yields and Fed rate hike expectations. The ETF shows minimal operational activity with $0 revenue but maintains a strong balance sheet with $13.41 billion in assets against negligible liabilities. Technical indicators signal bearish momentum with moving averages overwhelmingly negative, though RSI levels suggest potential oversold conditions.
While silver faces near-term headwinds from monetary policy, structural demand from industrial applications and inflation hedging provides long-term support. Key risks include Fed policy volatility and dollar strength, but the trust's pure-play silver exposure offers strategic diversification. Current levels may present accumulation opportunities for investors with multi-year horizons.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
